Pfizer's presentation

1. Cowen and Company Health Care Conference
Pfizer Oncology
Andy Schmeltz
Global President, Pfizer Oncology
March 14, 2018

2. 2
Forward Looking Statements
This presentation includes forward-looking statements about, among other things,
Pfizer’s oncology in-line products and product candidates, including anticipated
regulatory submissions, approvals, performance and potential benefits of Pfizer's
oncology products and product candidates, that are subject to substantial risks
and uncertainties that could cause actual results to differ materially from those
expressed or implied by such statements.
Additional information regarding these factors can be found in Pfizer’s Annual
Report on Form 10-K for the fiscal year ended December 31, 2017 and in our
subsequent reports on Form 10-Q, including in the sections thereof captioned
“Risk Factors” and “Forward-Looking Information and Factors that May Affect
Future Results”, as well as in our subsequent reports on Form 8-K, all of which
are filed with the U.S. Securities and Exchange Commission (SEC) and available
at www.sec.gov and www.pfizer.com.
The forward-looking statements in this presentation speak only as of the original
date of this presentation, and we undertake no obligation to update or revise any
of these statements.

3. 3
Pfizer Oncology Growth Trajectory
Growing in-line portfolio fueled by IBRANCE & XTANDI with
potential for multiple launches on the horizon
Curve is for illustrative purposes only
*numbers for 2018-2020 reflect potential approvals and indications that are expected and may not materialize
Opportunistic & Niche Growth & LeadershipMindset
GLASDEGIB
TALAZOPARIB
DACOMITINIB
LORLATINIB
# Approved
Medicines* 2 3 5 5 5 6 7 10 12 14 14
# Approved
Indications* 3 5 7 8 8 9 11 17 20 21 28
E* E* E*2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
Revenue$B

4. 4
A Rich Oncology Pipeline
1 Registration/Approvals: Only includes major regions (US, EU, JPN, CHN).
* Additional clinical studies being conducted in other tumor types/segments and earlier phases.
utomilumab
(PF-05082566)(B164)
13
Phase 1
p-cadherin LP DART
(PF-06671008)(B783)
Angiogenesis
Cell Signal
Transduction /
Oncogenic Driver
Immunotherapy
Cell Cycle &
Metabolism
Antibody Drug
Conjugate
Therapeutic
Vaccine
VBIR1
(PF-06753512)(B779)
Anti-PD1
(PF-06801591)(B801)
GD3
(PF-06688992)(B802)
NG-HER2
(PF-06804103)(C054)
BCMA CD3
(PF-06863135)(C107)
UCART19
(PF-06883541)(C119)
gedatolisib
(PF-05212384)(B215)
OX-40
(PF-04518600)(B060)
PTK7
(PF-06647020)(B766)
EGFR T790M
(PF-06747775)(B797)
Anti-MCSF
(PD-360324)(A626)
axitinib*
RCC Adj
6
Phase 3
palbociclib*
BC
avelumab*
NSCLC, Ovarian, RCC,
Gastric, urothelial,SCCHN
talazoparib*
gBRCA mut mBC, CRPC
enzalutamide*
CRPC, HSPC
lorlatinib
ALK+ NSCLC 1L
sunitinib
RCC Adj (EU)
dacomitinib*
NSCLC (US,EU)
lorlatinib
ALK+ NSCLC 2L+
(US,EU,JPN)
Registration1
bosutinib*
CML 1L (EU)
gemtuzumab
ozogamicin
AML (EU)
enzalutamide*
CRPC (US,EU)
6
Phase 2
4
glasdegib*
AML (Fit & Unfit)
avelumab*
NSCLC, SCLC, H&N,
Melanoma, TNBC, MCC
talazoparib*
CRPC
sunitinib
Pediatric GIST
crizotinib*
ALCL / Neuroblastoma
(pediatric CRCs)
as of February, 2018

5. 5
• Partner with key
stakeholders in the
breast and prostate
cancer communities
• Generate evidence
for broader and
optimal use
• Talazoparib: PARP
inhibitior
• Avelumab: backbone
PD-L1 therapy
• Identify and
interrogate rational
combinations with IO
and non-IO
mechanisms
• Innovative and
meaningful patient
engagement
• Advancing access
via outcomes and
real world evidence
• Redefining life with
cancer
Key Focus Areas
IBRANCE &
XTANDI*
Pipeline
Focused to Realize Our Vision
To Be a Leader in Oncology by Speeding Cures and Accessible
Breakthrough Medicines to Patients, Redefining Life with Cancer
*Pfizer and Astellas jointly commercialize XTANDI in the United States

6. Q&A
Andy Schmeltz
Global President, Pfizer Oncology